menu
    • menu
    [{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NX-5948","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NX-5948","moa":"BTK","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NX-5948","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NX-5948","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"J.P. Morgan Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"NX-5948","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ J.P. Morgan Securities","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ J.P. Morgan Securities"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NX-5948","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"NX-5948","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nurix Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"Nurix Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Nurix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NX-5948","moa":"","graph1":null,"graph2":null,"graph3":"Nurix Therapeutics","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Nurix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Nurix Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for NX-5948

    Menu

    NX-5948

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nurix’s BTK Degrader NX-5948 Shows Positive Results in Waldenstrom’s

                            Details : NX-5948 is a brain penetrant, small molecule degrader of BTK. NX-5948 is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory Waldenstrom’s Macroglobulinemia

                            Brand Name : NX-5948

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2024

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : J.P. Morgan

                            Deal Size : $188.6 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Nurix Therapeutics Completes Public Offering with Underwriters’ Option Fully Exercised

                            Details : Nurix will use net proceeds to fund clinical development of NX-5948, a small molecule BTK degrader for B-cell malignancies.

                            Brand Name : NX-5948

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 16, 2024

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : J.P. Morgan

                            Deal Size : $188.6 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : J.P. Morgan Securities

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

                            Details : Nurix will use proceeds to fund clinical development of NX-5948, a small molecule BTK degrader for treating B-cell malignancies.

                            Brand Name : NX-5948

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 11, 2024

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : J.P. Morgan Securities

                            Deal Size : $175.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nurix Reports Clinical Evidence of CNS Activity of NX-5948 for B Cell Malignancies

                            Details : NX-5948 is an orally available, selective degrader of Bruton’s tyrosine kinase. Currently, it is being evaluated with patients for the treatment of B cell malignancies.

                            Brand Name : NX-5948

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 09, 2024

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nurix Receives FDA Fast Track Designation for NX-5948 for CLL and SLL

                            Details : NX-5948 is an investigational, orally bioavailable, small molecule degrader of BTK. It is currently being evaluated in patients with relapsed or refractory B cell malignancies.

                            Brand Name : NX-5948

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 16, 2024

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to...

                            Details : NX-5948 is an investigational, orally bioavailable, small molecule degrader of BTK. NX-5948 has been designed to lack cereblon immunomodulatory activity for potential applications in indications where sparing immunomodulatory activity may be beneficial.

                            Brand Name : NX-5948

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 15, 2022

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual Europea...

                            Details : NX-5948 is an investigational, orally bioavailable, small molecule degrader of BTK that, unlike NX-2127, has been designed to lack cereblon immunomodulatory activity for potential applications in indications where sparing immunomodulatory activity may be...

                            Brand Name : NX-5948

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 10, 2022

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed

                            Nurix Therapeutics

                            U.S.A arrow
                            The Pharmacy Technology
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degra...

                            Details : NX-5948 was able to cross the blood brain barrier in preclinical models, degrade BTK in both microglia and central nervous system (CNS) resident lymphoma cells, and exert anti-lymphoma activity in a model of primary central nervous system lymphoma (PCNSL...

                            Brand Name : NX-5948

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 17, 2022

                            Lead Product(s) : NX-5948

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth